World Pharma Today: Powering Through Into 2025 With A Strong Foundation

In a recent article with World Pharma Today, Campbell Bunce, CSO of Abzena shared his views on modality shifts in 2024, and what to expect it 2025 within the complex biologics and bioconjugates space

In its advent to be the standalone ready-reckoner in the pharma domain, World Pharma Today presented an array of expert predictions for 2025 from leading voices in the pharmaceutical industry. From groundbreaking advancements in bioconjugates and cell and gene therapies to the integration of digital solutions and innovative device technologies, these insights reveal the trends shaping the future of pharma and healthcare. Key themes include supply chain efficiency, patient-centric solutions, platform standardization, and leveraging data-driven approaches for accelerated drug development.

Author: Campbell Bunce, Chief Scientific Officer

2024 marked the shift to complex modalities with bi and tri-specific antibodies being conjugated to a wide variety of payloads from cytotoxics to nucleotides. With innovative options for more precise targeting and different payloads, there’s been an explosion in thinking of where and how these new bespoke conjugated molecules can be applied. Pharma has moved past simple Antibody-Drug Conjugations (ADCs), which have proven the approach but have surfaced some issues with clinical safety and complex manufacturing controls (CMC).

As we move into 2025 and developers apply more learnings from the first phase of bioconjugates, upfront de-risking of development and manufacturing is a must to support both early scientific and longer-term commercial success. By taking a toolbox of proven conjugation technologies, well understood biology and chemistry simplified with a platform approach, along with complementary analytical services, will allow focus of expertise and resources on the novel value-add areas.

I believe 2025 will also see a burgeoning demand for standalone analytical services as the impacts of the Biosecure Act and import tariffs on industry-wide complex supply chains play out. A holistic approach for development, characterization and commercial manufacturing will be vital to achieve the full therapeutic potential of these new technically challenging modalities.

Read The Full Article